Counterpoint Mutual Funds LLC purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 76,743 shares of the company's stock, valued at approximately $382,000.
Other large investors also recently modified their holdings of the company. Hohimer Wealth Management LLC raised its stake in shares of GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after purchasing an additional 2,658 shares in the last quarter. SBI Securities Co. Ltd. raised its position in shares of GoodRx by 13.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock worth $100,000 after buying an additional 2,748 shares in the last quarter. Citizens Financial Group Inc. RI acquired a new stake in shares of GoodRx in the 1st quarter worth approximately $44,000. Headlands Technologies LLC boosted its holdings in shares of GoodRx by 213.2% in the first quarter. Headlands Technologies LLC now owns 14,830 shares of the company's stock valued at $65,000 after acquiring an additional 10,095 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of GoodRx by 6.4% during the first quarter. Swiss National Bank now owns 171,700 shares of the company's stock valued at $757,000 after acquiring an additional 10,300 shares during the period. 63.77% of the stock is owned by institutional investors and hedge funds.
GoodRx Trading Down 0.7%
NASDAQ:GDRX opened at $4.04 on Wednesday. The stock has a market cap of $1.40 billion, a PE ratio of 40.40, a price-to-earnings-growth ratio of 1.77 and a beta of 1.23. GoodRx Holdings, Inc. has a fifty-two week low of $3.31 and a fifty-two week high of $7.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. The stock's 50-day moving average is $4.34 and its two-hundred day moving average is $4.40.
GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company had revenue of $203.07 million for the quarter, compared to analyst estimates of $205.72 million. During the same quarter in the prior year, the business posted $0.08 earnings per share. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, equities research analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.
Insider Activity at GoodRx
In other news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $4.05, for a total value of $64,864.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.17% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
GDRX has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $6.00 target price on shares of GoodRx in a research report on Monday, August 11th. Raymond James Financial cut GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, GoodRx currently has a consensus rating of "Hold" and an average price target of $5.80.
Check Out Our Latest Report on GoodRx
GoodRx Profile
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Stories
Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
